《Nanomedicine & Biointerfaces at the Limit: Precision Delivery, Diagnostics, Sequencing, Regeneration, and Safe Human Interfaces》 is a flagship-scale research volume exploring what happens when nanoscale engineering begins to interact directly with living systems.

Abstract

《Nanomedicine & Biointerfaces at the Limit: Precision Delivery, Diagnostics, Sequencing, Regeneration, and Safe Human Interfaces》 is a flagship-scale research volume exploring what happens when nanoscale engineering begins to interact directly with living systems. The central question is not simply: Can nanoparticles deliver medicine? It is: Can nanoscale systems safely sense, enter, communicate with, modify, support, and eventually integrate with living matter? This book approaches nanomedicine as a complete systems problem. Its central pathway is: Nanoparticle → Body → Target → Cell → Payload → Clearance. Every stage matters. A therapeutic nanoparticle that reaches the bloodstream but not the target may fail. A carrier that reaches the target but cannot enter the appropriate cell may fail. A system that enters the cell but cannot release its payload may fail. A therapy that performs its intended function but accumulates indefinitely or triggers unacceptable immune responses may also fail. Nanomedicine therefore cannot be evaluated through delivery efficiency alone. The entire biological journey must be engineered. The book develops the Nano Therapeutic Systems Index: NTSI = (Targeting_n × Payload_n × Control_n × Clearance_n) / (1 + OffTarget_n + Immunogenicity_n + Toxicity_n) The NTSI is introduced as a research comparison framework rather than a universal medical law. Its purpose is to force therapeutic performance, biological control, clearance, immune response, toxicity, and off-target effects into the same analytical frame. A nanosystem is not successful merely because it performs one task extremely well. It must function within a living system. This leads to one of the central principles of the book: Performance without biological compatibility is not successful engineering. The research begins with nanoscale delivery systems. Lipid nanoparticles, polymeric nanoparticles, inorganic nanoparticles, protein-based carriers, hybrid structures, vesicles, and responsive nanomaterials are examined through size, surface chemistry, charge, morphology, stability, payload loading, release kinetics, circulation, biodistribution, and clearance. The book emphasizes that the biological identity of a nanoparticle may differ from its manufactured identity. Once introduced into biological fluids, proteins, lipids, metabolites, and other molecules may adsorb onto its surface and form a biological corona. This can change targeting, uptake, circulation, immune recognition, and toxicity. Surface engineering therefore becomes a biological design problem. Targeting forms another major research domain. Passive accumulation, ligand-mediated targeting, receptor recognition, microenvironment-responsive systems, cell-specific delivery, organ targeting, and barrier crossing are studied as part of a broader targeting architecture. The book distinguishes between reaching a region and reaching the correct biological compartment. Tumor tissue is not the same as a tumor cell. A cell membrane is not the same as the cytoplasm. The cytoplasm is not the same as the nucleus. The bloodstream is not the same as the brain. Targeting therefore becomes hierarchical: Organ → Tissue → Cell → Organelle → Molecular Target. Endosomal escape is treated as a major engineering bottleneck. A delivery system may enter a cell successfully and still fail if its payload remains trapped inside intracellular compartments. The book therefore examines membrane disruption, pH-responsive systems, ionizable materials, fusogenic mechanisms, carrier degradation, trafficking pathways, and intracellular release. Gene and RNA delivery form an important technological layer. Nucleic-acid medicines require protection, transport, cellular entry, release, expression, and eventual clearance. The research examines mRNA, siRNA, gene-editing payloads, oligonucleotides, and other programmable molecular therapies through the broader framework of controlled intracellular delivery. Nanopores create another major branch of the book. Biological and solid-state nanopores may enable single-molecule sensing, nucleic-acid analysis, protein characterization, molecular identification, and highly sensitive diagnostics. At these scales, individual molecules can become measurable events. The book explores pore geometry, ionic transport, translocation dynamics, signal-to-noise ratio, surface chemistry, molecular capture, temporal resolution, and signal interpretation. This leads naturally into sequencing. DNA and RNA sequencing are only part of the future molecular readout landscape. Protein sequencing, post-translational modification analysis, molecular fingerprinting, nanopore sensing, zero-mode waveguides, atomic-force methods, and hybrid single-molecule techniques could expand biological measurement far beyond current genomic information. The research therefore asks: How much of biology can eventually become readable at the level of individual molecules? Diagnostics form another major section. Lab-on-chip systems, microfluidics, nanosensors, optical probes, electrochemical detection, plasmonic sensors, magnetic nanoparticles, molecular assays, and point-of-care platforms are examined as integrated diagnostic systems. The goal is not merely higher sensitivity. Useful diagnostics must combine: Sensitivity Specificity Speed Robustness Interpretability Manufacturability Clinical usefulness A sensor capable of detecting extremely small signals may still be clinically weak if false positives, sample preparation, calibration, device variability, or data interpretation remain unresolved. Biosensors therefore become coupled measurement systems rather than isolated detectors. Nanoelectrodes and bioelectronic interfaces extend the field from chemical measurement into electrical interaction with living systems. Nanoscale electrodes, neural interfaces, flexible electronics, tissue-integrated sensors, electrochemical interfaces, and implantable devices may support recording, stimulation, closed-loop regulation, prosthetic control, and long-term physiological monitoring. Here, the engineering problem changes again. The interface must survive both worlds. It must satisfy the requirements of electronics and biology simultaneously. Electrical performance alone is insufficient. Mechanical compliance, inflammation, encapsulation, tissue motion, corrosion, charge transfer, long-term stability, sterilization, and removal or replacement all become central. This leads to a broader principle: The biointerface is not simply where the device touches the body. It is where two engineering regimes negotiate coexistence. Regenerative nanomaterials form another major research direction. Nanofibers, hydrogels, extracellular-matrix-inspired structures, bioactive surfaces, porous scaffolds, conductive materials, and responsive systems may help guide cell adhesion, differentiation, tissue organization, vascularization, nerve growth, and repair. At this level, a material is no longer merely supporting tissue. It may begin to communicate information to cells through chemistry, stiffness, topology, electrical signals, and spatial organization. The research therefore explores how nanoscale structure can influence biological regeneration. Bioelectronics extends this concept further. Future interfaces may combine sensing, computation, stimulation, drug delivery, adaptive control, and communication. A system may sense a biological state, interpret it, respond to it, and continue learning from subsequent measurements. This creates the possibility of closed-loop biological systems: Sense → Interpret → Decide → Act → Measure Again. Artificial intelligence may become deeply involved in this loop. AI can support signal interpretation, molecular pattern recognition, imaging, biosensor analysis, sequencing, pharmacokinetics, individualized dosing, device calibration, digital twins, and predictive models. However, the book emphasizes that biological AI systems must remain uncertainty-aware, interpretable, verifiable, and constrained by safety. High predictive accuracy does not eliminate the need for biological validation. Pharmacokinetics and biodistribution therefore remain central. Absorption, distribution, metabolism, degradation, retention, excretion, immune recognition, organ accumulation, and long-term persistence determine whether nanoscale systems can become clinically viable. The book examines how size, shape, surface chemistry, elasticity, charge, protein corona, and material composition influence these processes. Clearance is treated as a design variable rather than an afterthought. A nanosystem should not merely arrive correctly. It must also leave correctly. This leads to a broader engineering objective: Designed Entry → Controlled Function → Predictable Exit. Safety is embedded throughout the entire research architecture. NanoEHS is not reserved for the final chapter. Toxicity, immunogenicity, environmental release, occupational exposure, persistence, degradation products, reproductive effects, lifecycle behavior, manufacturing residues, and ethical implications are treated as design constraints from the beginning. This creates the principle of Safer-by-Design Nanomedicine. The research asks not only whether a system works, but whether unnecessary hazards can be removed before large-scale deployment. Clinical